This segment focuses on the development, commercialization, and support of ambulatory cardiac monitoring solutions, primarily the Zio service. Research and development activities include continuous improvement of the Zio patch, development of advanced algorithms for arrhythmia detection, and integration of AI/ML for improved diagnostic accuracy. The core technology is a wearable, single-use biosensor that continuously records ECG data. This segment addresses the needs of patients at risk for arrhythmias, enabling physicians to diagnose and manage conditions like atrial fibrillation. Market positioning is strong due to the Zio service's long-term continuous monitoring capabilities and ease of use. Competitive advantages include a large database of patient data and a focus on improving patient outcomes through early detection and diagnosis. Future opportunities include expansion into new geographic markets and the development of new diagnostic tools. Regulatory and clinical aspects are critical, with a focus on obtaining and maintaining FDA clearances and conducting clinical trials to validate the efficacy of the Zio service. Partnerships with healthcare providers and technology companies are essential for market access and integration with existing clinical workflows.